Abstract
Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.
Original language | English (US) |
---|---|
Pages (from-to) | 486-488 |
Number of pages | 3 |
Journal | European urology |
Volume | 78 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2020 |
ASJC Scopus subject areas
- Urology